These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1232 related articles for article (PubMed ID: 18614861)
1. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861 [TBL] [Abstract][Full Text] [Related]
2. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905 [TBL] [Abstract][Full Text] [Related]
3. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336 [TBL] [Abstract][Full Text] [Related]
4. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients. De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650 [TBL] [Abstract][Full Text] [Related]
5. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis. Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113 [TBL] [Abstract][Full Text] [Related]
6. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN. Bánhegyi D; Katlama C; da Cunha CA; Schneider S; Rachlis A; Workman C; De Meyer S; Vandevoorde A; Van De Casteele T; Tomaka F Curr HIV Res; 2012 Mar; 10(2):171-81. PubMed ID: 22339125 [TBL] [Abstract][Full Text] [Related]
7. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. Cahn P; Fourie J; Grinsztejn B; Hodder S; Molina JM; Ruxrungtham K; Workman C; Van De Casteele T; De Doncker P; Lathouwers E; Tomaka F AIDS; 2011 Apr; 25(7):929-39. PubMed ID: 21346512 [TBL] [Abstract][Full Text] [Related]
8. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS. Arathoon E; Schneider S; Baraldi E; Lim PL; Opravil M; Van De Casteele T; Lavreys L Int J STD AIDS; 2013 Jan; 24(1):12-7. PubMed ID: 23440570 [TBL] [Abstract][Full Text] [Related]
9. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. Molina JM; Podsadecki TJ; Johnson MA; Wilkin A; Domingo P; Myers R; Hairrell JM; Rode RA; King MS; Hanna GJ AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1505-14. PubMed ID: 18160008 [TBL] [Abstract][Full Text] [Related]
10. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline. Arribas JR; Clumeck N; Nelson M; Hill A; van Delft Y; Moecklinghoff C HIV Med; 2012 Aug; 13(7):398-405. PubMed ID: 22413874 [TBL] [Abstract][Full Text] [Related]
11. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D; Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869 [TBL] [Abstract][Full Text] [Related]
12. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial. Hill A; Marcelin AG; Calvez V HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995 [TBL] [Abstract][Full Text] [Related]
13. Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730. González-García J; Cohen D; Johnson M; Sloan L; Fredrick L; Naylor C; da Silva B; Bernstein B; AIDS Res Hum Retroviruses; 2010 Aug; 26(8):841-5. PubMed ID: 20672994 [TBL] [Abstract][Full Text] [Related]
14. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. Arribas JR; Horban A; Gerstoft J; Fätkenheuer G; Nelson M; Clumeck N; Pulido F; Hill A; van Delft Y; Stark T; Moecklinghoff C AIDS; 2010 Jan; 24(2):223-30. PubMed ID: 20010070 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. Katlama C; Esposito R; Gatell JM; Goffard JC; Grinsztejn B; Pozniak A; Rockstroh J; Stoehr A; Vetter N; Yeni P; Parys W; Vangeneugden T; AIDS; 2007 Feb; 21(4):395-402. PubMed ID: 17301557 [TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. Blanche S; Bologna R; Cahn P; Rugina S; Flynn P; Fortuny C; Vis P; Sekar V; van Baelen B; Dierynck I; Spinosa-Guzman S AIDS; 2009 Sep; 23(15):2005-13. PubMed ID: 19724191 [TBL] [Abstract][Full Text] [Related]
18. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K; Antivir Ther; 2012; 17(7):1351-61. PubMed ID: 23075703 [TBL] [Abstract][Full Text] [Related]
19. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial. Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640 [TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS; AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]